Bio-Path Holdings, Inc. (BPTH)
| Market Cap | 18.77M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -10.72M |
| Shares Out | 3.69M |
| EPS (ttm) | -3.00 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | January 14 |
| Last Price | $4.04 |
| Previous Close | $3.94 |
| Change ($) | 0.10 |
| Change (%) | 2.54% |
| Day's Open | 3.91 |
| Day's Range | 3.91 - 4.20 |
| Day's Volume | 252,031 |
| 52-Week Range | 3.07 - 7.57 |
Trial to Evaluate Ability of BP1002, Targeting Bcl-2 Protein, to Treat Refractory/Relapsed Lymphoma and Chronic Lymphocytic Leukemia Patients Trial to Evaluate Ability of BP1002, Targeting Bcl...
Bio-Path Holdings' (BPTH) CEO Peter Nielsen on Q3 2020 Results - Earnings Call Transcript
Conference Call to be Held Today at 8:30 A.M. ET Conference Call to be Held Today at 8:30 A.M. ET
HOUSTON, Nov. 06, 2020 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ: BPTH), a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to deve...
BPTH stock received a boost on Thursday after Bio-Path received a notice of allowance for a strategic patent for its candidate Prexigebersen. The post Bio-Path Holdings News: Why BPTH Stock Is...
Growing Patent Estate Creates Value and Supports Key Combination Therapies Growing Patent Estate Creates Value and Supports Key Combination Therapies
HOUSTON, Sept. 09, 2020 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ: BPTH), a biotechnology company leveraging its proprietary DNAbilize™ liposomal delivery and antisense technology...
Bio-Path (BPTH) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Bio-Path Holdings Inc (BPTH) CEO Peter Nielsen on Q2 2020 Results - Earnings Call Transcript
Conference Call to be Held Today at 8:30 A.M. ET Conference Call to be Held Today at 8:30 A.M. ET
Combination of Prexigebersen, Decitabine and Venetoclax Is Expected to Have Several Potential Pathways to Registration Combination of Prexigebersen, Decitabine and Venetoclax Is Expected to Ha...
HOUSTON, Aug. 07, 2020 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ: BPTH), a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to de...
Bio-Path Holdings, Inc. (BPTH) CEO Peter Nielsen on Q1 2020 Results - Earnings Call Transcript
Conference Call to be Held Today at 8:30 A.M. ET Conference Call to be Held Today at 8:30 A.M. ET
To say the least, Bio-Path Holdings Inc. (NASDAQ: BPTH) stock has taken a beating in the past five years.
On Friday, March 6, oncology drug development company Bio-Path Holdings Inc. (NASDAQ: BPTH) reported fiscal year 2019 results.
HOUSTON, March 11, 2020 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to de...
What is it like to have a stock plunge 90% in less than a year and wipe out a huge amount of market capitalization?
Tap five stocks with increasing P/E ratios to try an out-of-the-box approach.
HOUSTON, Jan. 08, 2020 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ: BPTH), a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to de...
Bio-Path (BPTH) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Combination of Prexigebersen and Decitabine Showed Encouraging Safety and Efficacy Results Combination of Prexigebersen and Decitabine Showed Encouraging Safety and Efficacy Results
HOUSTON, Nov. 25, 2019 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (Nasdaq:BPTH), a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to dev...
HOUSTON, Nov. 21, 2019 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (Nasdaq:BPTH), a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to dev...
Phase 1 Clinical Trial to Evaluate Ability of BP1002, Targeting Bcl-2 Protein, to Treat Refractory/Relapsed Lymphoma and Chronic Lymphocytic Leukemia Patients Phase 1 Clinical Trial to Evaluat...
Bio-Path (BTPH) earnings for the biotechnology company's third quarter of 2019 saw BTPH stock taking a wild ride on Friday.
Bio-Path Holdings, Inc (BPTH) CEO Peter Nielsen on Q3 2019 Results - Earnings Call Transcript
Brings 25 Years of Experience in Business Development and Marketing Brings 25 Years of Experience in Business Development and Marketing
HOUSTON, Sept. 03, 2019 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ: BPTH), a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to d...
HOUSTON, Aug. 26, 2019 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to dev...
Bio-Path Holdings, Inc. (BPTH) CEO Peter Nielsen on Q1 2019 Results - Earnings Call Transcript
Bio-Path rocketed Monday after withdrawing its December offering for stocks and warrants. Bio-Path is working on a number of cancer treatments.
Bio-Path Holdings Inc.'s stock rocketed 48% in morning trade Monday, after the biotechnology company focused on cancer treatments filed to withdraw a common stock offering.
Bio-Path Holdings (BPTH) CEO, Peter Nielsen on Q4 2018 Results - Earnings Call Transcript
Bio-Path Holdings Inc. (NASDAQ: BPTH) shares are on a rampage, with its second day of more than doubling. Shares actually were halted at multiple points during the day for volatility spikes.
Bio-Path Holdings Inc (BPTH) shares are on a tear, advancing over 160 percent on roughly 37 times their average volume Wednesday and trading up more than 200 percent Thursday afternoon.
About BPTH
Bio-Path Holdings operates as a clinical and preclinical stage oncology focused RNAi nano particle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction. Its lead drug candidate is prexigebersen, which is in Phase II clinical trials for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome; and in Phase IIa clinical t... [Read more...]
| Industry Biotechnology | Founded 2007 |
| CEO Peter H. Nielsen | Employees 9 |
| Stock Exchange NASDAQ | Ticker Symbol BPTH |
Analyst Forecasts
According to one analyst, the rating for BPTH stock is "Buy" and the 12-month stock price forecast is 10.00.